Krystal Biotech, Inc. (KRYS)
- Previous Close
184.48 - Open
185.09 - Bid 183.94 x 100
- Ask 185.17 x 100
- Day's Range
181.90 - 187.34 - 52 Week Range
93.95 - 219.34 - Volume
494,142 - Avg. Volume
281,803 - Market Cap (intraday)
5.291B - Beta (5Y Monthly) 0.82
- PE Ratio (TTM)
46.74 - EPS (TTM)
3.94 - Earnings Date Nov 4, 2024 - Nov 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
207.22
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
www.krystalbio.comRecent News: KRYS
View MorePerformance Overview: KRYS
Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRYS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRYS
View MoreValuation Measures
Market Cap
5.29B
Enterprise Value
4.74B
Trailing P/E
46.63
Forward P/E
26.53
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
32.58
Price/Book (mrq)
6.31
Enterprise Value/Revenue
28.51
Enterprise Value/EBITDA
39.49
Financial Highlights
Profitability and Income Statement
Profit Margin
63.73%
Return on Assets (ttm)
0.31%
Return on Equity (ttm)
14.20%
Revenue (ttm)
166.23M
Net Income Avi to Common (ttm)
105.94M
Diluted EPS (ttm)
3.94
Balance Sheet and Cash Flow
Total Cash (mrq)
559.61M
Total Debt/Equity (mrq)
0.92%
Levered Free Cash Flow (ttm)
-26.91M